Polaryx Therapeutics Inc (NASDAQ:PLYX) stock is trading higher Thursday morning following an early announcement regarding its capital structure and clinical timeline. The clinical-stage biotechnology company confirmed the closing of a $10 million private investment in public equity (PIPE) financing round on Thursday.

Details Of The PIPE Financing

The financing consisted of an aggregate of 2,502,696 shares of common stock. Investors locked in these shares at an average purchase price of approximately $4 per share. Polaryx stated it will not file a registration statement with the SEC registering the resale of these common shares.

Funding The SOTERIA Phase 2 Trial

Management plans to combine the $10 million gross proceeds with existing cash equivalents to launch its Phase 2 SOTERIA basket trial. The study evaluates the company’s lead drug candidate, PLX-200, across multiple lysosomal storage disorder (LSD) indications.

“This financing provides us with the runway to launch and reach key anticipated clinical milestones within the SOTERIA basket trial,” CEO Alex Yang stated in the release, adding that it extends the operating runway through the second quarter of 2027.

Regulatory Catalyst Context

The upcoming open-label trial targets four distinct LSDs: CLN2, CLN3, Krabbe disease, and Sandhoff disease. Chief Medical Officer Lisa L. Bollinger, M.D., noted that clinical development work with their CRO is underway for a planned launch in the second half of 2026. Bollinger highlighted that Polaryx has “Fast Track Designation from the Food and Drug Administration (“FDA”) in-hand for all four planned indications.”

Clinical Timeline Expectations

The company previously received a safe-to-proceed letter from the FDA in October. Polaryx plans to establish SOTERIA trial sites across the U.S., Europe, and Asia, utilizing natural history data as a control arm for the CLN2 and CLN3 cohorts.

PLYX Stock Price Activity: Polaryx Therapeutics shares were up 8.76% at $2.73 at the time of publication on Thursday. The stock is trading near its 52-week low of $2.06, according to Benzinga Pro data.

Photo Courtesy: MMD Creative on Shutterstock.com